Cancer Research UK’s commercial arm, Cancer Research Technology (CRT), and University College London (UCL) are teaming up with Stevenage-based Tusk Therapeutics to develop and commercialise an immunotherapy targeting a molecule known to suppress the immune system in cases of cancer. 

The deal will see Tusk gaining exclusive worldwide rights to develop and market the drug in question, which targets a molecule discovered through Cancer Research UK-funded research. The exact therapeutic target has not yet been revealed.

In return for the exclusive rights, CRT will receive an upfront payment (undisclosed), future success-based milestone and royalty payments, all of which will be shared with UCL.

In addition, Tusk has entered into a three-year collaboration with CRT and UCL to help fund preclinical projects led by CRT’s own Dr Sergio Quezada and UCL’s Professor Karl Peggs. Their work will involve the investigation of antibodies in a number of different cancer models prior to their preclinical and clinical development. Once clinically developed, Tusk will take on the responsibility of speeding up any potential candidates’ route to

Their work will involve the investigation of antibodies in a number of different cancer models prior to their preclinical and clinical development. Once clinically developed, Tusk will take on the responsibility of speeding up any potential candidates’ route to

Their work will involve the investigation of antibodies in a number of different cancer models prior to their preclinical and clinical development. Once clinically developed, Tusk will take on the responsibility of speeding up any potential candidates’ route to clinic.

“We are proud to work together with Cancer Research UK and the group of Dr Quezada,” said Luc Dochez, CEO of Tusk Therapeutics. “The collaboration fits Tusk’s strategy of working with top researchers in the immune-oncology field and to bring promising assets from early stage discovery through development and to the clinic.”

Dr Phil L’Huillier, CRT’s director of business management, also commented on the partnership: “This collaboration brings together Cancer Research UK’s and UCL’s world-leading immune-oncology expertise with Tusk Therapeutics’ growing industry reputation for developing promising immune-modulating antibodies.

“It’s one of several projects now in our portfolio focused on the up-and-coming field of immune-oncology that we hope will accelerate progress towards exciting new treatments for cancer patients.”

Advertisements